We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 28 for:    Recruiting, Not yet recruiting Studies | obsessive compulsive disorder | Child
Previous Study | Return to List | Next Study

Task Control Circuit Targets for Obsessive Compulsive Behaviors in Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03584945
Recruitment Status : Recruiting
First Posted : July 12, 2018
Last Update Posted : December 22, 2022
Sponsor:
Collaborators:
Columbia University
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Kate D. Fitzgerald, Columbia University

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study will use magnetic resonance imaging (MRI) to assess the function and structure of overlapping task control circuits in children with a range of Obsessive-Compulsive symptoms (OCS). The functioning of task control circuits will be assessed using the well-validated Multisource interference task (MSIT). This study will also assess functional and anatomical connectivity within task control circuits in the same children, and determine whether disturbances in these overlapping circuits are associated with Obsessive-Compulsive Disorder (OCD) symptom severity. Behavioral measures will be administered to further assess regulatory, learning and memory functions. Children with OCD will then be offered a standard course of up to 12 cognitive behavioral therapy (CBT), either via remote video conference sessions or in person visits when clinically indicated, before scanning (along with age-and gender-matched control participants) in order to assess how these circuits may change with treatment. Children with subclinical OC symptoms will be offered referral for treatment on an as-needed basis. In addition, de-identified data may be used in the future to conduct secondary data analyses. As more about OC symptoms and neurobiological mechanisms of interest in the current study are understood, data may be used to answer questions beyond those described in this protocol. All study procedures will be conducted on-site at Columbia University/the New York State Psychiatric Institute (New York, NY) and the University of Michigan's outpatient Child and Adolescent Psychiatry (Ann Arbor, Michigan).

Condition or disease Intervention/treatment Phase
Obsessive-compulsive Disorders and Symptoms in Children Behavioral: Cognitive Behavioral Therapy Other: Community Referral as appropriate Not Applicable

Detailed Description:
Recruitment is ongoing.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 105 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Children ages 7-14 with OCD, obsessive compulsive symptoms, or healthy controls
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Task Control Circuit Targets for Obsessive Compulsive Behaviors in Children
Actual Study Start Date : March 24, 2019
Estimated Primary Completion Date : June 30, 2023
Estimated Study Completion Date : June 30, 2023

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Obsessive Compulsive Disorder Behavioral: Cognitive Behavioral Therapy
The treatment team will offer a course of up to 12 cognitive behavioral therapy (CBT) (45 minute sessions for 12 to 16 weeks), augmented by medication treatment when clinically indicated based on the clinical treatment standards. Due to Covid, therapy sessions are offered via remote video conference (in clinic sessions made available if clinically indicated). Cognitive-behavioral therapy (CBT) is a treatment based on learning and cognitive theories. CBT for Obsessive-Compulsive Disorder (OCD) involves gradually exposing patients to anxiety provoking stimuli while having patients refrain from engaging in compulsive rituals and/or avoidance behaviors. There are three major components of CBT treatment for OCD, specifically: (1) exposure to anxiety provoking stimuli, (2) response prevention, and (3) cognitive techniques intended to decrease anxiety during the exposure and response prevention processes.
Subclinical Obsessive-Compulsive symptoms (OCS) Other: Community Referral as appropriate
Participants with Obsessive Compulsive Symptoms will be referred to the community for treatment
No Intervention: Healthy Control


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Blood oxygen-level dependent (BOLD) functional MRI signal during a cognitive conflict task [ Time Frame: up to 16 weeks after baseline (following 12 weeks of therapy for intervention groups); approximately 15-20 minutes ]

Secondary Outcome Measures :
  1. Blood oxygen-level dependent (BOLD) functional connectivity MRI of task control circuits [ Time Frame: up to 16 weeks after baseline (following 12 weeks of therapy for intervention groups);approximately 10 minutes ]
  2. Child Yale-Brown Obsessive Compulsive Scale [ Time Frame: up to 16 weeks after baseline (following 12 weeks of therapy for intervention groups);approximately 1 hour ]
    Child Yale-Brown Obsessive Compulsive Scale (CYBOCS) is scored on a scale of 0 to 40, with 40 being the most severe.

  3. Obsessive Compulsive Inventory - Child Version (OCI-CV) [ Time Frame: baseline assessment of all participants (OCD, subclinical OCS and HC) ]
    Self-report assessment of obsessive compulsive symptoms, non-clinical to clinical range.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   7 Years to 14 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Obsessive-Compulsive Disorder (OCD) patient group

INCLUSION:

  1. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Diagnosis of OCD as the principal problem
  2. Not on psychotropic medication and not receiving current psychotherapy for OCD
  3. Written informed assent by the participants and consent by the parent
  4. Participants and a parent/guardian must be able to read and understand English

EXCLUSION

  1. DSM-5 current diagnosis of major depressive disorder, or substance/alcohol abuse
  2. DSM-5 lifetime diagnosis of psychotic disorder, bipolar disorder, eating disorder, pervasive developmental disorder, or substance/alcohol abuse
  3. Individuals who are currently receiving CBT, other forms of psychotherapy, or psychotropic medications (stable doses of stimulants or other types of ADHD medications - e.g. Guanfacine - are allowable for OCD subjects with comorbid attention deficit hyperactivity disorder following investigator review of medication; on day of study scan, subjects must be willing to refrain from taking medication until after scan is completed)
  4. Active suicidal ideation
  5. Females who are pregnant or nursing
  6. Major medical or neurological problems
  7. Presence of metallic device or dental braces
  8. Intelligence Quotient (IQ)<80
  9. A current or past diagnosis of pediatric autoimmune neuropsychiatric disorders associated with streptococcus (PANDAS)
  10. Individuals who are currently receiving CBT, other forms of psychotherapy, or psychotropic medications
  11. Individuals who have received a full course of CBT in the past
  12. A positive pregnancy test
  13. Positive urine screen for illicit drugs

Healthy controls

INCLUSION:

  1. Written informed assent by the participants and consent by the parent
  2. Participants and a parent/guardian must be able to read and understand English

EXCLUSION:

  1. Any current or lifetime psychiatric diagnosis
  2. Active suicidal ideation
  3. Females who are pregnant or nursing
  4. Major medical or neurological problems
  5. Presence of metallic device or dental braces
  6. IQ <80
  7. A current or past diagnosis of pediatric autoimmune neuropsychiatric disorders associated with streptococcus (PANDAS)
  8. A positive pregnancy test
  9. Positive urine screen for illicit drugs

Obsessive Compulsive Symptoms

INCLUSION:

  1. Presence of obsession(s) and/or compulsion(s) but no current diagnosis of OCD (i.e.,<1 hour/day, no more than mild interference or distress)
  2. Not on psychotropic medication and not receiving current psychotherapy for OCD
  3. Written informed assent by the participants and consent by the parent
  4. Participants and a parent/guardian must be able to read and understand English

EXCLUSION:

  1. DSM-5 current diagnosis of major depressive disorder, attention-deficit hyperactivity disorder, Tourette's/Tic Disorder, or substance/alcohol abuse
  2. DSM-5 lifetime diagnosis of psychotic disorder, bipolar disorder, eating disorder, pervasive developmental disorder, or substance/alcohol abuse
  3. Active suicidal ideation
  4. Females who are pregnant or nursing
  5. Major medical or neurological problems
  6. Presence of metallic device or dental braces
  7. IQ<80
  8. A current or past diagnosis of pediatric autoimmune neuropsychiatric disorders associated with streptococcus (PANDAS)
  9. Individuals who are currently receiving CBT, other forms of psychotherapy, or psychotropic medications
  10. Individuals who have received a full course of CBT in the past
  11. Positive urine screen for illicit drugs
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03584945


Contacts
Layout table for location contacts
Contact: Caroline Risdon, BA (646) 774-5868 caroline.risdon@nsypi.columbia.edu

Locations
Layout table for location information
United States, Michigan
University of Michigan Active, not recruiting
Ann Arbor, Michigan, United States, 48109
United States, New York
New York State Psychiatric Institute Recruiting
New York, New York, United States, 10032
Contact: Caroline Risdon, BS    646-774-5868    caroline.risdon@nyspi.columbia.edu   
Contact: Martine Fontaine, BS    646-774-6072    martine.fontaine@nyspi.columbia.edu   
Principal Investigator: Rachel Marsh, PhD         
Sponsors and Collaborators
University of Michigan
Columbia University
National Institute of Mental Health (NIMH)
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Kate D. Fitzgerald, Professor, Columbia University
ClinicalTrials.gov Identifier: NCT03584945    
Other Study ID Numbers: HUM00144074
1R01MH114958-01A1 ( U.S. NIH Grant/Contract )
R01MH115024-01A1 ( U.S. NIH Grant/Contract )
First Posted: July 12, 2018    Key Record Dates
Last Update Posted: December 22, 2022
Last Verified: December 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Participant data will be shared between sites at the University of Michigan and Columbia. A DUA will also be established per University guidelines as required. Coded, de-identified IPD will be shared with the NIMH data repository, RDoCdb.
Supporting Materials: Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Obsessive-Compulsive Disorder
Compulsive Behavior
Mental Disorders
Anxiety Disorders
Impulsive Behavior